AllSci News
Incyclix Bio raises USD 5m Series B to advance CDK2 inhibitor in breast cancer study
Incyclix Bio, a cell cycle-focused oncology company headquartered in Research Triangle Park, North Carolina, has raised an additional USD 5 million in...
China approves GSK’s Exdensur for chronic rhinosinusitis with nasal polyps in adults
GSK announced that China’s National Medical Products Administration (NMPA) has approved Exdensur (depemokimab) as add-on therapy with intranasal corticosteroids for adult patients…
Sidewinder Therapeutics raises USD 137 million Series B for bispecific antibody-drug conjugates
San Diego-based Sidewinder Therapeutics has closed a USD 137 million Series B financing round to advance its pipeline of bispecific antibody-drug conjugates...
ReAlta Life Sciences closes USD 40m financing round for pegtarazimod HIE program
Norfolk, Virginia-based ReAlta Life Sciences Inc. has closed an oversubscribed USD 40 million financing round to advance pegtarazimod, its lead candidate...
Insmed discontinues brensocatib development in hidradenitis suppurativa after CEDAR study fail
Insmed Discontinues Brensocatib HS Program After CEDAR Study Fails to Beat Placebo
Grand Pharma and University of Hong Kong partner on novel antibacterial drug development
Grand Pharmaceutical Group Limited (HKEX: 00512), the Hong Kong-listed diversified pharmaceutical company, has announced a strategic partnership with the University of Hong…
Alzheon doses oral amyloid oligomer inhibitor with APOE4 corrector function in Alzheimer's
Alzheon has dosed the first human subjects in a Phase 1 trial of ALZ-507, an oral small molecule designed to inhibit the formation of neurotoxic soluble...
Greenwich LifeSciences files to expand patent for lead immunotherapy to cover non-HLA-A*02 breast cancer patients
Greenwich LifeSciences, Inc. (USA, Nasdaq: GLSI) announced new patent claims for its Fast Track-designated asset GLSI-100, a peptide-based immunotherapy composed of the…
Hemispherian's GLIX1 initiates Phase I/IIa trial in recurrent glioblastoma patients
Hemispherian AS, an Oslo-based oncology company, announced the initiation of a first-in-human Phase I/2a GLIX1 clinical trial in glioblastoma on April 8,...
Merck and Zhifei Biological restructure China vaccine distribution deal for Gardasil 9
Gardasil 9, RotaTeq, and Pneumovax 23 sit at the center of a restructured exclusive distribution and co-promotion agreement signed April 2, 2026, between...
Corbus agrees with FDA on Phase III direction of CSPC-licensed Nectin-4 ADC
Corbus Pharmaceuticals (Nasdaq: CRBP) announced that the FDA has aligned with its proposed registrational study designs for CRB-701, a Nectin-4–targeting...
Methodist Hospital Research Institute receives USD 2.47m NIAID grant for gasdermin C research
The Methodist Hospital Research Institute in Houston has received a four-year R01 award totaling USD 2,469,932 from the National Institute of Allergy and...
Airna's RNA-editing therapy targets PiZ mutation in alpha-1 antitrypsin deficiency via ADAR recruitment
AIRNA doses first patient in Phase 1 trial of AIR-001, an RNA-editing therapy for alpha-1 antitrypsin deficiency
MHRA accepts Savara's Molbreevi application for autoimmune pulmonary alveolar proteinosis treatment
Savara Inc. has submitted a Marketing Authorisation Application (MAA) to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for MOLBREEVI...
Merck initiates tender offer for Terns Pharmaceuticals
Merck Expands Hematology Pipeline via USD 3.0 Billion Tender Offer for Terns Pharmaceuticals
The AllSci Brief
Systematic R&D and deal news. Daily.